Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
Abraxane, accident, adjacent, al, alcohol, anterior, articulating, Aug, automatically, baseline, Book, Carboplatin, cardiomyopathy, CardioOncol, CCMIA, cerebrovascular, Cetuximab, chest, clawback, Cmax, CPS, CT, detachable, disorder, Eastern, ECG, ECHO, erroneously, evidenced, excessive, facilitate, fixed, freestanding, FTC, gadolinium, Gr, haplotype, hypercholesterolemia, hyperlipidemia, hypertension, hypertrophic, hyponatremia, incrementally, intake, Israel, JACC, Longitudinal, lot, magnitude, Mar, Mersana, mild, move, MRI, MT, myocardium, neck, Nivolumab, odd, Oncologist, onset, Orange, Palbociclib, Palestine, radiology, recovery, repurchase, restarted, resumption, retrospectively, rich, Sarocchi, Secretary, sequalae, Serial, settle, soft, Tamura, Taxotere, Tazemetostat, tissue, TPS, unconfirmed, Undergoing, unexercised, unfair, vertebral, vi, Waliany
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view